|
2024 Book Chapter Role of Functional Imaging in NENsChan, David L., Pattison, David A. and Kong, Grace (2024). Role of Functional Imaging in NENs. Endocrinology. (pp. 1-24) Cham, Switzerland: Springer. doi: 10.1007/978-3-030-67823-4_8-1 |
|
2023 Journal Article Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRIArnfield, Evyn G., Tam, Laura, Pattison, David A., Younger, John, Chikatamarla, Venkata Avinash, Wyld, David, Burge, Matthew, McCormack, Louise, Ladwa, Rahul and Ramsay, Stuart (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology, 30 (6), 2676-2691. doi: 10.1007/s12350-023-03345-w |
|
2023 Journal Article Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma managementPathmanathan, Shivanshan, Tariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C., Gan, Chun Loo and Roberts, Matthew J. (2023). Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management. European Journal of Nuclear Medicine and Molecular Imaging, 51 (1), 295-303. doi: 10.1007/s00259-023-06380-4 |
|
2023 Journal Article Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06Barry, Nathaniel, Francis, Roslyn J., Ebert, Martin A., Koh, Eng-Siew, Rowshanfarzad, Pejman, Hassan, Ghulam Mubashar, Kendrick, Jake, Gan, Hui K., Lee, Sze T., Lau, Eddie, Moffat, Bradford A., Fitt, Greg, Moore, Alisha, Thomas, Paul, Pattison, David A., Akhurst, Tim, Alipour, Ramin, Thomas, Elizabeth L., Hsiao, Edward, Schembri, Geoffrey P., Lin, Peter, Ly, Tam, Yap, June, Kirkwood, Ian, Vallat, Wilson, Khan, Shahroz, Krishna, Dayanethee, Ngai, Stanley, Yu, Chris ... Scott, Andrew M. (2023). Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06. European Journal of Nuclear Medicine and Molecular Imaging, 50 (13), 3970-3981. doi: 10.1007/s00259-023-06371-5 |
|
2023 Conference Publication Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND TrialRoberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Journal Article Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)Li, Minmin, Chan, David L., Tapia Rico, Gonzalo, Cehic, Gabrielle, Lawrence, Ben, Wyld, David, Pattison, David A., Kong, Grace, Hicks, Rodney, Michael, Michael, Kiberu, Andrew Ddembe, Lim, Jennifer, Clifton-Bligh, Roderick, Tsang, Venessa, Roach, Paul J., Leyden, John, Diakos, Connie I., Price, Timothy J. and Pavlakis, Nick (2023). Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). Neuroendocrinology, 113 (3), 281-288. doi: 10.1159/000526848 |
|
2023 Conference Publication Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271 |
|
2022 Journal Article Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic dietBennett, O. A., Ramsay, S. C., Malacova, E., Bourgeat, P., Goodman, S. J., Dunn, C. J., Robinson, B. M., Lee, K. and Pattison, D. A. (2022). Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic diet. European Journal of Hybrid Imaging, 6 (1) 29, 1-16. doi: 10.1186/s41824-022-00150-5 |
|
2022 Journal Article PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialButeau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Banks, Patricia, Beaulieu, Alexis, Chua, Wei, Dhiantravan, Nattakorn, Ford, Kate, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J ... for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. The Lancet Oncology, 23 (11), 1389-1397. doi: 10.1016/S1470-2045(22)00605-2 |
|
2022 Journal Article 99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis: Functional Imaging-Histopathologic CorrelationWang, Ray, Better, Nathan, Sivaratnam, Dinesh, Westcott, James, Forehan, Simon, Christie, Michael, Pattison, David A. and Fourlanos, Spiros (2022). 99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis: Functional Imaging-Histopathologic Correlation. Clinical Nuclear Medicine, 47 (9), E582-E584. doi: 10.1097/RLU.0000000000004332 |
|
2022 Journal Article Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)Tariq, Arsalan, McGeorge, Stephen, Pearce, Adam, Rhee, Handoo, Wood, Simon, Kyle, Samuel, Marsh, Philip, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Westera, Jurjen, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2022). Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urologic Oncology: Seminars and Original Investigations, 40 (6), 276.e1-276.e9. doi: 10.1016/j.urolonc.2022.03.007 |
|
2022 Conference Publication TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC)Pathmanathan, Shivanshan, Tariq, Arsalan, Gan, Chun Loo, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Philip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C. and Roberts, Matthew (2022). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, 3-7 June 2022. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2022.40.16_suppl.4540 |
|
2022 Journal Article All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than OthersEmmett, Louise, Pattison, David A. and Roberts, Matthew J. (2022). All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others. European urology oncology, 5 (3), 283-284. doi: 10.1016/j.euo.2022.04.002 |
|
2022 Journal Article The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspectiveLee, Sze Ting, Emmett, Louise M., Pattison, David A., Hofman, Michael S., Bailey, Dale L., Latter, Melissa J., Francis, Roslyn J. and Scott, Andrew M. (2022). The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspective. Journal of Nuclear Medicine, 63 (6), 819-822. doi: 10.2967/jnumed.122.263996 |
|
2022 Conference Publication Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <SUP>177</SUP>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final resultsPavlakis, Nick, Ransom, David Turner, Wyld, David, Sjoquist, Katrin Marie, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, Simone, Zalcberg, John Raymond and Turner, Harvey (2022). Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Journal Article The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparisonTariq, Arsalan, Kwok, Michael, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Marsh, Phillip, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Westera, Jurjen, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John W., Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2022). The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urologic Oncology: Seminars and Original Investigations, 40 (2) 66.e1, 66.e1-66.e9. doi: 10.1016/j.urolonc.2021.11.006 |
|
2022 Journal Article [18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHDScott, Ashleigh P., Thomas, Paul, Pattison, David A., Francis, Leo, Ridge, Paula, Tey, Siok-Keen and Kennedy, Glen A. (2022). [18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD. Bone Marrow Transplantation, 57 (3), 517-519. doi: 10.1038/s41409-022-01571-3 |
|
2022 Journal Article Lymph node classification in E-PSMA reporting guidelines for PSMA-PETArnfield, Evyn G., Roberts, Matthew J. and Pattison, David A. (2022). Lymph node classification in E-PSMA reporting guidelines for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 50 (1), 1-2. doi: 10.1007/s00259-022-05943-1 |
|
2021 Journal Article Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer stagingChikatamarla, Venkata Avinash, Okano, Satomi, Jenvey, Peter, Ansaldo, Alexander, Roberts, Matthew J., Ramsay, Stuart C., Thomas, Paul A. and Pattison, David A. (2021). Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. EJNMMI Research, 11 (1) 128, 128. doi: 10.1186/s13550-021-00869-5 |
